ME02385B - Sulfonamidi za prevenciju dijabetesa - Google Patents

Sulfonamidi za prevenciju dijabetesa

Info

Publication number
ME02385B
ME02385B MEP-2016-71A MEP7116A ME02385B ME 02385 B ME02385 B ME 02385B ME P7116 A MEP7116 A ME P7116A ME 02385 B ME02385 B ME 02385B
Authority
ME
Montenegro
Prior art keywords
diabetes
compound
sulfonamide
preventing diabetes
use according
Prior art date
Application number
MEP-2016-71A
Other languages
German (de)
English (en)
French (fr)
Unknown language (me)
Inventor
Lorenzo Piemonti
Luisa Daffonchio
Marcello Allegretti
Original Assignee
Dompe Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Farm Spa filed Critical Dompe Farm Spa
Publication of ME02385B publication Critical patent/ME02385B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MEP-2016-71A 2009-10-06 2010-10-06 Sulfonamidi za prevenciju dijabetesa ME02385B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09172365A EP2308485A1 (en) 2009-10-06 2009-10-06 Sulfonamides for the prevention of diabetes
EP10768898.8A EP2485724B1 (en) 2009-10-06 2010-10-06 Sulfonamides for the prevention of diabetes
PCT/EP2010/064920 WO2011042465A1 (en) 2009-10-06 2010-10-06 Sulfonamides for the prevention of diabetes

Publications (1)

Publication Number Publication Date
ME02385B true ME02385B (me) 2016-09-20

Family

ID=41716341

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2016-71A ME02385B (me) 2009-10-06 2010-10-06 Sulfonamidi za prevenciju dijabetesa

Country Status (24)

Country Link
US (2) US8846755B2 (enExample)
EP (2) EP2308485A1 (enExample)
JP (1) JP5745526B2 (enExample)
KR (1) KR101737656B1 (enExample)
CN (1) CN102639128B (enExample)
AU (1) AU2010305384B2 (enExample)
BR (1) BR112012007989B1 (enExample)
CA (1) CA2776021C (enExample)
CY (1) CY1117599T1 (enExample)
DK (1) DK2485724T3 (enExample)
EA (1) EA021788B1 (enExample)
ES (1) ES2570463T3 (enExample)
HR (1) HRP20160399T1 (enExample)
HU (1) HUE028132T2 (enExample)
IL (1) IL219038A (enExample)
ME (1) ME02385B (enExample)
MX (1) MX2012004087A (enExample)
NZ (1) NZ599171A (enExample)
PL (1) PL2485724T3 (enExample)
RS (1) RS54693B1 (enExample)
SI (1) SI2485724T1 (enExample)
SM (1) SMT201600126B (enExample)
WO (1) WO2011042465A1 (enExample)
ZA (1) ZA201202462B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
EP2308485A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes
EP3281937A1 (en) * 2016-08-09 2018-02-14 Dompé farmaceutici S.p.A. Sulfonamides as gpr40- and gpr120-agonists
WO2018067548A1 (en) 2016-10-03 2018-04-12 The Children's Medicial Center Corporation Prevention and treatment of diabetic nephropathy
EP4686469A1 (en) 2024-07-31 2026-02-04 Dompé farmaceutici SpA Cxcl8 inhibitors for use in the treatment of diabetes-associated comorbidities

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303249B1 (it) 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
ITMI20010206A1 (it) * 2001-02-02 2002-08-02 Dompe Spa Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
US20040242498A1 (en) * 2003-02-27 2004-12-02 Collins Tassie L. CXCR3 antagonists
HRP20090681T1 (hr) 2004-03-23 2010-02-28 Dompe' S.P.A. Derivati 2-fenilpropionske kiseline i farmaceutski pripravci koji ih sadrže
DE602004003673T2 (de) 2004-03-25 2007-10-04 Dompe' Pha.R.Ma S.P.A. Verwendung von N-(2-Aryl-propionyl)-sulfonamiden zur Behandlung von Rückenmarkverletzungen
KR20110014141A (ko) * 2008-03-20 2011-02-10 카롤러스 테라퓨틱스, 인코포레이티드 염증을 치료하는 방법
EP2308484A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
EP2308485A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes

Also Published As

Publication number Publication date
PL2485724T3 (pl) 2016-07-29
BR112012007989B1 (pt) 2019-10-22
SI2485724T1 (sl) 2018-12-31
KR101737656B1 (ko) 2017-05-18
NZ599171A (en) 2014-03-28
AU2010305384A1 (en) 2012-04-26
CA2776021C (en) 2017-08-01
ES2570463T3 (es) 2016-05-18
ZA201202462B (en) 2013-06-26
US20150011639A1 (en) 2015-01-08
US20130059908A1 (en) 2013-03-07
CA2776021A1 (en) 2011-04-14
US8846755B2 (en) 2014-09-30
US9556115B2 (en) 2017-01-31
EP2485724B1 (en) 2016-02-10
DK2485724T3 (en) 2016-05-02
RS54693B1 (sr) 2016-08-31
CN102639128A (zh) 2012-08-15
IL219038A (en) 2015-07-30
JP2013506703A (ja) 2013-02-28
KR20120083889A (ko) 2012-07-26
SMT201600126B (it) 2016-07-01
AU2010305384B2 (en) 2016-02-04
EA021788B1 (ru) 2015-08-31
EA201270512A1 (ru) 2012-11-30
EP2308485A1 (en) 2011-04-13
CY1117599T1 (el) 2017-04-26
CN102639128B (zh) 2014-02-26
EP2485724A1 (en) 2012-08-15
WO2011042465A1 (en) 2011-04-14
JP5745526B2 (ja) 2015-07-08
HRP20160399T1 (hr) 2016-05-20
HUE028132T2 (en) 2016-11-28
MX2012004087A (es) 2012-08-23
IL219038A0 (en) 2012-06-28
HK1174557A1 (en) 2013-06-14

Similar Documents

Publication Publication Date Title
NZ607794A (en) N-acylsulfonamide apoptosis promoters
ES2491140T3 (es) Derivados de flavona enantioméricamente puros para el tratamiento de trastornos proliferativos y procesos para su preparación
EA201201378A1 (ru) Определенные аминопиримидины, композиции на их основе и способы их использования
UA112317C2 (uk) Похідні 2-(1,2,3-триазол-2-іл)бензаміду та 3-(1,2,3-триазол-2-іл)піколінаміду як антагоністи рецептора орексину
MX2009011579A (es) Pirimidinonas como moduladores de caseina cinasa ii (ck2).
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
CA2757418C (en) Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
UA109421C2 (uk) Фармацевтична композиція, яка містить ліганди сигма-рецептора
MY165918A (en) Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof
MX2009011208A (es) Derivados de acido nicotinico como moduladores del receptor de glutamato metabotropico-5.
RU2014114466A (ru) ИНДАЗОЛ-3-КАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ WNT/β-КАТЕНИНА
WO2011159550A3 (en) Lysophosphatidic acid receptor antagonist and uses thereof
BR112013025881A2 (pt) composto representado pela fórmula geral (i), composto ou um sal do mesmo, inibidor deagregação tau, inibidor de b-secretase, inibidor de agregação de b-proteína amiloide, composição farmacêutica, preparação oral ou parenteral e composto representado pela fórmula geral (ii)
NO20070458L (no) Aryl-pyridinderivater som 11-Beta-HSD1 inhibitorer
EA201071329A1 (ru) Диамидные производные адамантана и их применение
UA94606C2 (ru) Производные тиоксантина, композиция, которая их содержит, и их применение в терапии
MX2009006598A (es) Derivados de sulfamida como transferasa de carnitina palmitoil del higado (l-cptl).
GEP20135950B (en) New compositions containing 1-[2-(2,4-dimethyl-phenylsulfa-nyl)-phenyl]piperazine
WO2008015280A3 (de) Wässrige wirkstoffkonzentrate mit herbizider wirkung
EA201391018A1 (ru) Препараты иммуносупрессантов
WO2012044531A8 (en) Novel piperazine analogs with substituted heteroaryl groups as broad-spectrum influenza antivirals
ME02107B (me) Heteroaril jedinjenja kao ligandi 5-ht4 receptora
EA201270099A1 (ru) Транс-4-[[(5s)-5-[[[3,5-бис(трифторметил)фенил]метил](2-метил-2h-тетразол-5-ил)амино]-2,3,4,5-тетрагидро-7,9-диметил-1h-1-бензазепин-1-ил]метил]циклогексанкарбоновая кислота
HRP20080027T3 (hr) 4-hidroksi-4-metil-piperidin-1-karboksilna kiselina (4-metoksi-7-morfolin-4-il-benzotiazol-2-il)-amid
HRP20160399T1 (hr) Sulfonamidi, namijenjeni sprječavanju dijabetesa